X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
roxadustat fg-4592 (52) 52
index medicus (47) 47
anemia (42) 42
humans (30) 30
chronic kidney disease (29) 29
hypoxia (24) 24
urology & nephrology (24) 24
erythropoietin (22) 22
pharmacology & pharmacy (19) 19
roxadustat (19) 19
anemia - drug therapy (17) 17
epoetin-alpha (17) 17
chronic kidney-disease (16) 16
hypoxia-inducible factor (16) 16
animals (15) 15
erythropoiesis-stimulating agents (14) 14
glycine - analogs & derivatives (13) 13
renal insufficiency, chronic - complications (13) 13
prolyl hydroxylase inhibitor (12) 12
chronic kidney failure (11) 11
health aspects (11) 11
kidney diseases (11) 11
male (11) 11
anemia - etiology (10) 10
erythropoiesis (10) 10
fg-4592 (10) 10
hypoxia-inducible factors (10) 10
iron (10) 10
analysis (9) 9
ckd (9) 9
dialysis (9) 9
hematinics - therapeutic use (9) 9
hemodialysis-patients (9) 9
hepcidin (9) 9
glycine - therapeutic use (8) 8
hemoglobin (8) 8
hydroxylase inhibitor gsk1278863 (8) 8
hypoxia-inducible factor 1 - metabolism (8) 8
inflammation (8) 8
isoquinolines - therapeutic use (8) 8
mice (8) 8
pharmacokinetics (8) 8
care and treatment (7) 7
clinical trials (7) 7
expression (7) 7
hemodialysis (7) 7
hif (7) 7
hypoxia-inducible factor-proline dioxygenases - antagonists & inhibitors (7) 7
peripheral vascular disease (7) 7
pharmacology (7) 7
research (7) 7
transcription factors (7) 7
anemia - complications (6) 6
factor-i (6) 6
female (6) 6
gene-expression (6) 6
hif-1-alpha (6) 6
hydroxylase (6) 6
hydroxylases (6) 6
kidneys (6) 6
nephrology (6) 6
physiological aspects (6) 6
recombinant-human-erythropoietin (6) 6
renal insufficiency, chronic - metabolism (6) 6
adult (5) 5
anaemia (5) 5
dialysis patients (5) 5
gene expression (5) 5
hypoxia-inducible factor 1, alpha subunit - metabolism (5) 5
medical research (5) 5
pharmacodynamics (5) 5
renal anemia (5) 5
renal dialysis (5) 5
vadadustat (5) 5
young adult (5) 5
aged (4) 4
alpha (4) 4
anemia - metabolism (4) 4
biochemistry & molecular biology (4) 4
complications and side effects (4) 4
daprodustat (4) 4
development and progression (4) 4
fibrosis (4) 4
glycine - administration & dosage (4) 4
hematology (4) 4
hypoxia-inducible factor prolyl hydroxylase inhibitors (4) 4
intravenous iron (4) 4
iron-metabolism (4) 4
isoquinolines - administration & dosage (4) 4
kidney failure, chronic - complications (4) 4
medicine, experimental (4) 4
medicine, research & experimental (4) 4
middle aged (4) 4
molidustat (4) 4
oncology (4) 4
oxidative stress (4) 4
oxygen (4) 4
patients (4) 4
prolyl hydroxylase (4) 4
prolyl hydroxylase domain (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Cancer Research, ISSN 0008-5472, 2019, Volume 79, Issue 9, pp. 2327 - 2338
When pancreatic cancer cannot be removed surgically, patients frequently experience morbidity and death from progression of their primary tumor. Radiation... 
FOLFIRINOX | HIF-2-ALPHA | THERAPY | METASTASIS | ROXADUSTAT | ONCOLOGY | ADENOCARCINOMA | PHASE-II | ALPHA | TUMORS | GEMCITABINE
Journal Article
CANCER RESEARCH, ISSN 0008-5472, 05/2019, Volume 79, Issue 10, pp. 2564 - 2579
We hypothesized that candidate dependencies for which there are small molecules that are either approved or in advanced development for a nononcology... 
HYPOXIA-INDUCIBLE-FACTOR-1-ALPHA | HIF PROLYL HYDROXYLASES | GENE | ONCOLOGY | ANEMIA | HIF-1-ALPHA | HYPOXIA | SUPPRESSION | ROXADUSTAT FG-4592 | EXPRESSION | HIF1-ALPHA
Journal Article
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, ISSN 1079-5642, 09/2016, Volume 36, Issue 9, pp. 1782 - 1790
Objective Atherosclerotic lesions contain hypoxic areas, but the pathophysiological importance of hypoxia is unknown. Hypoxia-inducible factor-1 (HIF-1) is a... 
atherosclerosis | hypoxia | NITRIC-OXIDE SYNTHASE | MURINE ATHEROSCLEROSIS | apoptosis | macrophage | ALPHA | DEFICIENT MICE | PLAQUES | FOAM CELLS | ROXADUSTAT FG-4592 | INFLAMMATION | hypoxia-inducible factor 1 | TUMOR-SUPPRESSOR PROTEIN | PERIPHERAL VASCULAR DISEASE | HIF-1-ALPHA | HEMATOLOGY
Journal Article
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, ISSN 0931-0509, 10/2018, Volume 33, Issue 10, pp. 1690 - 1698
Journal Article
Plastic and Reconstructive Surgery, ISSN 0032-1052, 04/2019, Volume 143, Issue 4, pp. 769e - 779e
BACKGROUND:The hypoxia-inducible factor (HIF) pathway, regulated by prolyl hydroxylase, is central to tissue adaptation to ischemia. The authors tested whether... 
SURVIVAL | SURGERY | PRETREATMENT | ANGIOGENESIS | DIMETHYLOXALYLGLYCINE | ANEMIA | INDUCTION | ROXADUSTAT FG-4592 | DELAY | HYPOXIA-INDUCIBLE FACTORS | PROTECTS | Care and treatment | Enzyme inhibitors | Ischemia | Skin-grafting | Models | Hydroxylases | Health aspects | Testing | Necrosis
Journal Article
American Journal of Kidney Diseases, ISSN 0272-6386, 2016, Volume 67, Issue 6, pp. 912 - 924
Journal Article
Journal Article
Expert Opinion on Investigational Drugs, ISSN 1354-3784, 01/2018, Volume 27, Issue 1, pp. 125 - 133
Introduction: Anaemia is one of the hallmarks of advanced chronic kidney disease (CKD); it correlates with a lower quality of life and increased cardiovascular... 
erythropoiesis stimulating agents | chronic kidney disease | hepcidin | Anaemia | HIF | prolyl-hydroxylases domain | roxadustat | TRANSCRIPTION FACTORS | HOMEOSTASIS | FG-4592 | ERYTHROPOIETIN PRODUCTION | ERYTHROCYTOSIS | HYPOXIA-INDUCIBLE FACTORS | RESPONSES | INFLAMMATION | PROLYL-HYDROXYLASE | REGULATES HEPCIDIN | PHARMACOLOGY & PHARMACY
Journal Article
Journal of Pharmaceutical Sciences, ISSN 0022-3549, 03/2018, Volume 107, Issue 3, pp. 848 - 855
Chronic kidney disease (CKD) is accompanied by a variety of complications, typically renal anemia and kidney fibrosis. Accordingly, it is desirable to develop... 
nitric oxide | chronic kidney disease | renal anemia | kidney fibrosis | albumin | HYPOXIA-INDUCIBLE FACTOR | CHEMISTRY, MEDICINAL | INJURY | MECHANISMS | MESENCHYMAL TRANSITION | ROXADUSTAT FG-4592 | CHEMISTRY, MULTIDISCIPLINARY | RENAL FIBROSIS | ERYTHROPOIESIS-STIMULATING AGENTS | UNILATERAL URETERAL OBSTRUCTION | BIOLOGY | PHARMACOLOGY & PHARMACY | ANEMIA
Journal Article
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, ISSN 1661-6596, 08/2019, Volume 20, Issue 16, p. 3853
During the last decade, substantial advances have been made in the understanding of the complex molecular, immunological and cellular disturbances involved in... 
PLACEBO | ERYTHROPOIESIS | BIOCHEMISTRY & MOLECULAR BIOLOGY | ALPHA | PHASE-3 | ROXADUSTAT FG-4592 | CHEMISTRY, MULTIDISCIPLINARY | low-risk disease | ESA | STIMULATING AGENTS | treatment failure | EMA | LENALIDOMIDE | TRANSFUSION-DEPENDENT PATIENTS | ANEMIA | MDS
Journal Article
Kidney International, ISSN 0085-2538, 11/2016, Volume 90, Issue 5, pp. 923 - 925
The treatment of anemia with erythropoiesis-stimulating agents and iron supplementation has become the standard of care in patients with chronic kidney... 
UROLOGY & NEPHROLOGY | EPOETIN-ALPHA | ROXADUSTAT FG-4592 | CKD | Anemia - drug therapy | Hematinics - pharmacology | Hematinics - therapeutic use | Humans | Hypoxia-Inducible Factor-Proline Dioxygenases - antagonists & inhibitors | Renal Insufficiency, Chronic - complications | Anemia - etiology
Journal Article